Toward a Cancer Drug of Fungal Origin

Medicinal Research Reviews

Volumn 35, Issue 5, 2015, Pages 937-967

  Kornienko, Alexander ^a   Evidente, Antonio ^b   Vurro, Maurizio ^c   Mathieu, Véronique ^d   Cimmino, Alessio ^b   Evidente, Marco ^b   van Otterlo, Willem A L ^e   Dasari, Ramesh ^a   Lefranc, Florence ^f   Kiss, Robert ^d  

^a Texas State University   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c INSTITUTE OF SCIENCES OF FOOD PRODUCTION   (Italy)

^d UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^e STELLENBOSCH UNIVERSITY   (South Africa)

^f ERASME HOSPITAL   (Belgium)

Author keywords

Anguidine; Aphidicolin; Clinical trials; Drug resistance; Fumagillin; Fungal metabolites; Illudin S; Phenylahistin; Rhizoxin; Wortmannin

Indexed keywords

ANTINEOPLASTIC AGENT; APHIDICOLIN; APICIDIN; CHAETOCIN; COTYLENIN A; CYTOCHALASIN E; DESTRUXIN; DESTRUXIN B; DIACETOXYSCIRPENOL; EPOXYQUINOL B; FUMAGILLIN; GALIELLALACTONE; GLIOCLADICILLINS A; GLIOCLADICILLINS B; ILLUDIN S; NATURAL PRODUCT; PALMARUMYCIN CP1; PHENYLAHISTIN; RHIZOXIN; THERMOZYMOCIDIN; TRIORNICIN; UNCLASSIFIED DRUG; WORTMANNIN; ANDROSTANE DERIVATIVE; BIOLOGICAL PRODUCT; CYCLOHEXANE DERIVATIVE; MACROLIDE; PIPERAZINEDIONE; SESQUITERPENE; TRICHOTHECENE DERIVATIVE; UNSATURATED FATTY ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIODIVERSITY; CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG RESISTANCE; FUNGAL METABOLISM; FUNGUS; HUMAN; NONHUMAN; STUDY DESIGN; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG DESIGN; FEMALE; MALE; MOUSE; NEOPLASMS;

ANDROSTADIENES; ANIMALS; ANTINEOPLASTIC AGENTS; APHIDICOLIN; BIOLOGICAL PRODUCTS; CLINICAL TRIALS AS TOPIC; CYCLOHEXANES; DIKETOPIPERAZINES; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; FATTY ACIDS, UNSATURATED; FEMALE; FUNGI; HUMANS; MACROLIDES; MALE; MICE; NEOPLASMS; SESQUITERPENES; TRICHOTHECENES;

EID: 84938743842     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21348     Document Type: Article

References (201)

1. Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin 2009;59:111-137.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer J Clin 2014;64:9-29.
3. Paci A, Veal G, Bardin C, Leveque D, Widmer N, Beijnen J, Astier A, Chatelut E. Review of therapeutic drug monitoring of anticancer drugs. Part 1. Cytotoxics. Eur J Cancer 2014;50:2010-2019.
4. Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin 2013;63:249-279.
5. Taby R, Issa JP. Cancer epigenetics. CA Cancer J Clin 2010;60:376-392.
6. Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel D, Korbelik M, Moan J, Mroz P, Nowis D, Piette J, Wilson BC, Golab J. Photodynamic therapy of cancer: An update. CA Cancer J Clin 2011;61:250-281.
7. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin 2012;62:309-335.
8. Cook KM, Figg WD. Angiogenesis inhibitors: Current strategies and future prospects. CA Cancer J Clin 2010;60:222-243.
9. Cragg GM, Grothaus PG, Newman DJ. Impact of natural products on developing new anti-cancer agents. Chem Rev 2009;109:3012-3043.
10. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012;75:311-335.
11. Cragg GM, Newman DJ. Natural products: A continuing source of novel drug leads. Biochim Biophys Acta 2013;1830:3670-3695.
12. Qurishi Y, Hamid A, Majeed R, Hussain A, Qazi AK, Ahmed M, Zargar MA, Singh SK, Saxena AK. Interaction of natural products with cell survival and signaling pathways in the biochemical elucidation of drug targets in cancer. Future Oncol 2011;7:1007-1021.
13. Cerella C, Teiten MH, Radogna F, Dicato M, Diederich M. From nature to bedside: Pro-survival and cell death mechanisms as therapeutic targets in cancer treatment. Biotechnol Adv 2014;32:1111-1122.
14. Schnekenburger M, Dicato M, Diederich M. Plant-derived epigenetic modulators for cancer treatment and prevention. Biotechnol Adv 2014;32:1123-1132.
15. Demain AL. From natural products discovery to commercialization: A success story. J Ind Microbiol Biotechnol 2006;33:486-495.
16. Rappe MS, Giovannoni SJ. The uncultured microbial majority. Ann Rev Microbiol 2003;57:369-394.
17. Stevenson BS, Eichorst SA, Wertz JT, Schmidt TM, Breznak JA. New strategies for cultivation and detection of previously uncultured microbes. Appl Environ Microbiol 2004;70:4748-4755.
18. Turner WB, Aldridge DC. Fungal Metabolites II. London: Academic Press, Inc. Ltd.; 1983.
19. Dewick PM. Medicinal Natural Products. Chichester: John Wiley & Sons Ltd.; 1997.
20. Cole RJ, Jarvis BB, Schweikert MA. Handbook of Secondary Fungal Metabolites, Vol. III. Amsterdam: Academic Press; 2003.
21. Starratt AN, Loschiavo SR. The production of aphidicolin by Nigrospora sphaerica. Canad J Microbiol 1974;20:416-417.
22. Kanoh K, Konho S, Asari T, Harada T, Katada J, Muramatsu M, Kawashima H, Sekiya H, Uno I. (-)-Phenylahistin: A new mammalian cell cycle inhibitor produced by Aspergillus usts. Bioorg Med Chem Lett 1997;7:2847-2852.
23. Evidente A, Andolfi A, Cimmino A, Vurro M, Fracchiolla M, Charudattan R, Motta A. Ophiobolin E and 8-epi-ophiobolin J produced by Drechslera gigantea, potential mycoherbicide of weedy grasses. Phytochemistry 2006;67:2281-2287.
24. Saidou Balde E, Andolfi A, Bruyère C, Cimmino A, Lamoral-Theys D, Vurro M, Van Damme M, Altomare C, Mathieu V, Kiss R, Evidente A. Investigations of fungal secondary metabolites with anticancer activity. J Nat Prod 2010;73:969-971.
25. Andolfi A, Cimmino A, Vurro M, Berestetskiy A, Troise C, Zonno MC, Motta A, Evidente A. Agropyrenol and agropyrenal, phytotoxins from Ascochyta agropyrina var. nana, a fungal pathogen of Elitrigia repens. Phytochemistry 2012;79:102-108.
26. Junker B, Walker A, Hesse M, Lester M, Vesey D, Christensen J, Burgess B, Connors N. Pilot-scale process development and scale up for antifungal production. Bioproc Biosyst Eng 2009;32:443-458.
27. Escamilla-Silva E, Poggi-Varaldo H, Mayra M, De la Torre-Martínez, Guadalupe Sanchez Cornejo MA, Dendooven L. Selective production of bikaverin in a fluidized bioreactor with immobilized Gibberella fujikuroi. World J Microbiol Biotechnol 2001;17:469-474.
28. Xu ZN, Yang ST. Production of mycophenolic acid by Penicillium brevicompactum immobilized in a rotating fibrous-bed bioreactor. Enzyme Microb Technol 2007;40:623-628.
29. Barrios-González J, Mejía A. Production of secondary metabolites by solid-state fermentation. Biotechnol Annu Rev 1996;2:85-121.
30. Ooijkaas LP, Weber FJ, Buitelaar RM, Tramper J, Rinzema A. Defined media and inert supports: Their potential as solid-state fermentation production systems. Trends Biotechnol 2000;18:356-360.
31. Singhania RR, Patel AK, Soccol CR, Pandey A. Recent advances in solid-state fermentation. Biochem Eng J 2009;44:13-18.
32. Bills GF, Platas G, Fillola A, Jiménez MR, Collado J, Vicente F, Martín J, González A, Bur-Zimmermann J, Tormo JR, Peláez F. Enhancement of antibiotic and secondary metabolite detection from filamentous fungi by growth on nutritional arrays. J Appl Microbiol 2008;104:1644-1658.
33. Thammajaruk N, Sriubolmas N, Israngkul D, Meevootisom V, Wiyakrutta S. Optimization of culture conditions for mycoepoxydiene production by Phomopsis sp. Hant25. J Ind Microbiol Biotechnol 2011;38:679-685.
34. Bode HB, Bethe B, Höfs R, Zeeck A. Big effects from small changes: Possible ways to explore nature's chemical diversity. Chem Bio Chem 2002;3:619-627
35. Christian OE. Compton J, Christian KR, Mooberry SL, Valeriote FA, Crews P. Using jasplakinolide to turn on pathways that enable the isolation of new chaetoglobosins from Phomopsis asparagi. J Nat Prod 2005;68:1592-1597.
36. Scherlach K, Hertweck C. Discovery of aspoquinolones A-D, prenylated quinoline-2-one alkaloids from Aspergillus nidulans, motivated by genome mining. Org Biomol Chem 2006;4:3517-3520.
37. Vurro M, Bottalico A, Capasso R, Evidente A. Cytochalasins from Phytopathogenic Ascochyta and Phoma species. In (Upadhyay RK and Mukerji KG, Eds) Toxins in Plant Disease Development and Evolving Biotechnology. Oxford: IBH Publishing Co. Pvt. Ltd.; 1997. p 127-147.
38. Pettit RK. Mixed fermentation for natural product drug discovery. Appl Microbiol Biotechnol 2009;83:19-25.
39. Chiang Y-M, Szewczyk E, Nayak T, Sanchez JF, Lo H, Simityan H, Kuo E, Praseuth A, Watanabe K, Oakley BR, Wang CCC. Discovery of the emericellamide gene cluster: An efficient gene targeting system for the genomic mining of natural products in Aspergillus nidulans. Chem Biol 2008;15:527-532.
40. McCormick SP, Hohn TM. Accumulation of trichothecenes in liquid cultures of a Fusarium sporotrichioides mutant lacking a functional trichothecene C-15 hydroxylase. Appl Environ Microbiol 1997;63:1685-1688.
41. Nielsen J. Metabolic engineering. Appl Microbiol Biotechnol 2001;55:263-283.
42. Chen Y, Smanski MJ, Shen B. Improvement of secondary metabolite production in Streptomyces by manipulating pathway regulation. Appl Microbiol Biotechnol 2010;86:19-25.
43. Scherlach K, Hertweck C. Triggering cryptic natural product biosynthesis in microorganisms. Org Biomol Chem 2009;7:1753-1760.
44. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: An evolving paradigm. Nat Rev Cancer 2013;13:714-726.
45. Vadlapatla RK, Vadlapudi AD, Pal D, Mitra AK. Mechanisms of drug resistance in cancer chemotherapy: Coordinated role and regulation of efflux transporters and metabolizing enzymes. Curr Pharm Des 2013;19:7126-7140.
46. Chen C, Chen J, Zhao KN. Editorial: Signaling pathways in anti-cancer drug resistance. Curr Med Chem 2014;21:3007-3008.
47. Krakstad C, Chekenya M. Survival signalling and apoptosis resistance in glioblastomas: Opportunities for targeted therapeutics. Mol Cancer 2010;9:135.
48. Wang X, Peralta S, Moraes CT. Mitochondrial alterations during carcinogenesis: A review of metabolic transformation and targets for anticancer treatments. Adv Cancer Res 2013;119:127-160.
49. Paoli P, Giannoni E, Chiarugi P. Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta 2013;1833:3481-3498.
50. Burris HA 3rd. Overcoming acquired resistance to anticancer therapy: Focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol 2013;71:829-842.
51. Tsouris V, Joo MK, Kim SH, Kwon IC, Won YY. Nanocarriers that enable co-delivery of chemotherapy and RNAi agents for treatment of drug-resistant cancers. Biotechnol Adv 2014;32:1037-1050.
52. Patel NR, Pattni BS, Abouzeid AH, Torchilin VP. Nanopreparations to overcome multidrug resistance in cancer. Adv Drug Deliv Rev 2013;65:1748-1762.
53. Taby R, Issa JP. Cancer epigenetics. CA Cancer J Clin 2010;60:376-392.
54. Schnekenburger M, Dicato M, Diederich M. Plant-derived epigenetic modulators for cancer treatment and prevention. Biotechnol Adv 2014;32:1123-1132.
55. Kornienko A, Mathieu V, Rastogi SK, Lefranc F, Kiss R. Therapeutic agents triggering nonapoptotic cancer cell death. J Med Chem 2013;56:4823-4839.
56. Evidente A, Kornienko A, Cimmino A, Andolfi A, Lefranc F, Mathieu V, Kiss R. Fungal metabolites with anticancer activity. Nat Prod Rep 2014;31:617-627.
57. Patel S, Goyal A. Recent developments in mushrooms as anti-cancer therapeutics: A review. 3 Biotech 2012;2:1-15.
58. Penta JS. Anguidine (Diacetoxyscirpenol, NSC 141537). Natl Cancer Inst Clin Brochure 1975.
59. Adler S, Lowenbraun S, Birch B, Jarrell R, Garrard J. Anguidine-A broad Phase-II study of the southeastern cancer study-group. Cancer Treat Rep 1984;68:423-425.
60. Goodwin J, Bottomley R, Vaughn C, Frank J, Pugh R. Phase-II evaluation of anguidine in central nervous-system tumors-A southwest oncology group-study. Cancer Treat Rep 1983;67:285-286.
61. Bukowski R, Vaughn C, Bottomley R, Chen, T. Phase-II study of anguidine in gastrointestinal malignancies-A southwest oncology group-study. Cancer Treat Rep 1982;66:381-383.
62. Goodwin W, Stephens R, Mccracken J, Groppe C. Therapy for advanced colorectal-cancer with a combination of 5-FU and anguidine-A southwest oncology group-study. Cancer Treat Rep 1981;65:359-359.
63. Thigpen J, Vaughn C, Stuckey W. Phase-II trial of anguidine in patients with sarcomas unresponsive to prior chemotherapy-A southwest-oncology-group study. Cancer Treat Rep 1981;65:881-882.
64. Yap H, Murphy W, Distefano A, Blumenschein G, Bodey G. Phase-II study of anguidine in advanced breast-cancer. Cancer Treat Rep 1979;63:789-791.
65. Brundret KM, Dalzeil W, Hesp B, Jarvis JAJ, Neidle S. X-ray crystallographic determination of the structure of the antibiotic aphidicolin: A tetracyclic diterpenoid containing a new ring system. J Chem Soc Chem Commun 1972;1027-1028.
66. Dalzeil W, Hesp B, Stevenson KM, Jarvis JAJ. The structure and absolute configuration of the antibiotic aphidicolin: A tetracyclic diterpenoid containing a new ring system. J Chem Soc Perkin Trans I 1974;2841-2851.
67. Rizzo CJ, Smith AB. Aphidicolin synthetis studies: A sterocontrolled end game. J Chem Soc Perkin Trans I 1991;969-979.
68. Dai J, Hussain H, Draeger S, Schultz B, Curtan T, Pescitelli G, Floerke U, Krohn K. Metabolites from the fungus Phoma sp. 7210 associated with Aizoon canariense. Nat Prod Commun 2010;5:1175-1180.
69. Sessa C, Zucchetti M, Davoli E, Califano R, Cavalli F, Frustaci S, Gumbrell L, Sulkes A, Winograd B, Dincalci M. Phase-I and clinical pharmacological evaluation of aphidicolin glycinate. J Natl Cancer Inst 1991;83:1160-1164.
70. Iwasaki S, Kobayashi H, Funkawa J, Namikoshi M, Okura S, Sato Z, Matsuda I, Noda T. Studies on macrocyclic lactone antibiotic. VII. Structure of a phytotoxin "rhizoxin" produced Rhizopus chinensis. J Antibiot 1984;37:354-362.
71. Scherlach K, Busch B, Lackner G, Paszkowski U, Hertweck C. Symbiotic cooperation in the biosynthesis of a phytotoxin. Angew Chem Int Ed 2012;51:9615-9618.
72. McLeod HL, Murray LS, Wanders J, Setanoians A, Graham MA, Pavlidis N, Heinrich B, ten Bokkel Huinink WW, Wagener DJ, Aamdal S, Verweij J. Br J Cancer 1996;74:1944-1948.
73. Tolcher AW, Aylesworth C, Rizzo J, Izbicka E, Campbell E, Kuhn J, Weiss G, Von Hoff DD, Rowinsky EK. A Phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol 2000;11:333-338.
74. Hanauske AR, Catimel G, Aamdal S, Huinink WT, Paridaens R, Pavlidis N, Kaye SB, teVelde A, Wanders J, Verweij J. Phase II clinical trials with rhizoxin in breast cancer and melanoma. Br J Cancer 1996;73:397-399.
75. Verweij J, Wanders J, Gil T, Schoffski P, Catimel G, teVelde A, deMulder PHM. Phase II study of rhizoxin in squamous cell head and neck cancer. Br J Cancer 1996;73:400-402.
76. Kaplan S, Hanauske AR, Pavlidis N, Bruntsch U, teVelde A, Wanders J, Heinrich B, Verweij J. Single agent activity of rhizoxin in non-small-cell lung cancer: A Phase II trial of the EORTC early clinical trials group. Br J Cancer 1996;73:403-405.
77. Eble TE, Hanson FR. Fumagillin, an antibiotic from Aspergillus fumigatus H-3. Antibiot Chemother 1951;1:54-58.
78. Tarbell DS, Carman RM, Chapman DD, Cremer SE, Cross AD, Hufman KR, Kustmann M, Mc Corkindale NJ, Mc Mally JG, Rosowsk JrA, Varino FHL, West RL. The chemistry of fumagillin. J Am Chem Soc 83:3096-3113.
79. Birch AG, Hussain SF. Studies in realtion to byosynthesis. Part XXXVIII. A preliminary study of fumagillin. J Chem Soc (C) 1969:1473-1474.
80. Senyuva HZ, Gilbert J, Oeztuerkoglu S. Rapid analyses of fungal culture and dried figs for secondary metabolites by LC/TOF/MS. Anal Chim Acta 2008;617:97-106.
81. Vansteelandt M, Blanchet E, Egorov M, Petit F, Toupet L, Bondon A, Monteau F, Le Bizec B, Thomas OP, Pouchus YF, Bot RL, Grovel O. Ligerin, an antiproliferative chlorinated sesquiterpenoid from a a marine derived Penicillium strain. J Nat Prod 2013;76:297-301.
82. Arico-Muendel CC, Benjamin DR, Caiazzo TM, Centrella PA, Contonio BD, Cook CM, Doyle EG, Hannig G, Labenski MT, Searle LL, Lind K, Morgan BA, Olson G, Paradise CL, Self C, Skinner SR, Sluboski B, Svendsen JL, Thompson CD, Westlin W, White KF. Carbamate analogues of fumagillin as potent, targeted inhibitors of methionine aminopeptidase-2. J Med Chem 2009;52:8047-8056.
83. Anchel M, Hervey A, Robbins WJ. Antibiotic substances from basydiomycete. VII. Clitocybe illudens. Proc Natl Acad Sci USA 1950;36:300-305.
84. Tada M, Yamada Y, Bhacca NS, Nakanishi K, Ohashi M. Structure and reactions of illudin S (lampterol). Chem Pharm Bull 1964;12:853-855.
85. Nakanishi K, Ohashi M, Tada M, Yamada Y. Illudin S (lampterol). Tetrahedron 1965;21:1231-1246.
86. Engler M, Anke T, Sterner O. Production of antibiotics by Colybia nivalis, Omphalateus olearius, Flavoloschia, and a Pterula species on natural substrates. Biosciences 1998;53:318-324.
87. Seiden MV, Gordon AN, Bodurka DC, Matulonis UA, Penson RT, Reed E, Alberts DS, Weems G, Cullen M, McGuire WP. A Phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer. Gynecol Oncol 2006;101:55-61.
88. Kanoh K, Konho S, Katada J, Hayashi Y, Muramatsu M, Uno I. Antitumor activity of phenylahistin in vitro and in vivo. Biosci Biotechnol Biochem 1999;63:1130-1133.
89. Millward M, Mainwaring P, Mita A, Federico K, Lloyd GK, Reddinger N, Nawrocki S, Mita M, Spear MA. Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel. Invest New Drugs 2012;30:1065-1073.
90. MacMillan J, Vanstone AE, Yeboah SK. The structure of wortmannin, a steroidal fungal metabolite. Chem Comm 1968;613-614.
91. MacMillan J, Simpson TJ, Yeboah SK. Absolute stereochemistry of the fungal product, wortmannin. J Chem Soc Chem Commun 1972;1063.
92. Petcher TJ, Weber H-P, Kis Z. Crystal structure and absolute configuration of wortmannin and of wortmannin p-bromobenzoate. J Chem Soc Chem Commun 1972;1061-1062.
93. Thrane U, Hansen U. Chemical and physiological characterization of taxa in the Fusarium sambucinum complex. Mycopathologia 1995;129:183-190.
94. Li G-H, Wang H-B, Liu F-F, Dang L-Z, Li L, Yang Z-S, Xin X, Zhang K-Q. The chemical constituents of endophytic fungus Trichoderma sp. MFF-1. Chem Biodiver 2010;7:1790-1795.
95. Workman P, Clarke PA, Raynaud FI, van Montfort RL. Drugging the PI3 kinome: From chemical tools to drugs in the clinic. Cancer Res 2010;70:2146-2157.
96. Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008;27:5511-5526.
97. Yu K, Lucas J, Zhu T, Zask A, Gaydos C, Toral-Barza L, Gu J, Li F, Chaudhary I, Cai P, Lotvin J, Petersen R, Ruppen M, Fawzi M, Ayral-Kaloustian S, Skotnicki J, Mansour T, Frost P, Gibbons J. PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors. Cancer Biol Ther 2005;4:538-545.
98. Zhu T, Gu J, Yu K, Lucas J, Cai P, Tsao R, Gong Y, Li F, Chaudhary I, Desai P, Ruppen M, Fawzi M, Gibbons J, Ayral-Kaloustian S, Skotnicki J, Mansour T, Zask A. Pegylated wortmannin and 17-hydroxywortmannin conjugates as phosphoinositide 3-kinase inhibitors active in human tumor xenograft models. J Med Chem 2006;49:1373-1378.
99. Bhargava P, Marshall JL, Rizvi N, Dahut W, Yoe J, Figuera M, Phipps K, Ong VS, Kato A, Hawkins MJ. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res 1999;5:1989-1995.
100. Yin S-Q, Wang, J-J, Zhang C-M, Liu Z-P. The development of MetAP-2 inhibitors in cancer treatment. Curr Med Chem 2012;19:1021-1035.
101. Logothetis CJ, Wu KK, Finn LD, Daliani D, Figg W, Ghaddar H, Gutterman JU. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res 2001;7:1198-1203.
102. Herbst RS, Madden TL, Tran HT, Blumenschein GR, Meyers CA, Seabrooke LF, Khuri FR, Puduvalli VK, Allgood V, Fritsche HA, Hinton L, Newman RA, Crane EA, Fossella FV, Dordal M, Goodin T, Hong WK. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: Evidence for activity in non-small-cell lung cancer. J Clin Oncol 2002;20:4440-4447.
103. Tran HT, Blumenschein GR, Lu C, Meyers CA, Papadimitrakopoulou V, Fossella FV, Zinner R, Madden T, Smythe LG, Puduvalli VK, Munden R, Truong M, Herbst RS. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol 2004;54:308-314.
104. Stiede K, Eder J, Anthony S, Conkling P, Fayad L, Petrylak D, Sausville E, Verschraegen C, Bhat G. Phase I dose escalation safety/tolerance study of PPI-2458 in subjects with Non-Hodgkin's lymphoma or solid tumors. EJC Suppl 2006;4:45-45.
105. Shin SJ, Jeung H-C, Ahn JB, Rha SY, Roh JK, Park KS, Kim D-H, Kim C, Chung HC. A Phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. Invest New Drugs 2010;28:650-658.
106. Shin SJ, Ahn JB, Park KS, Lee YJ, Hong YS, Kim TW, Kim HR, Rha SY, Roh JK, Kim D-H, Kim C, Chung HC. A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. Invest New Drugs 2012;30:672-680.
107. Alexandre J, Kahatt C, Bertheault-Cvitkovic F, Faivre S, Shibata S, Hilgers W, Goldwasser F, Lokiec F, Raymond E, Weems G, Shah A, MacDonald JR, Cvitkovic E. A Phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors. Invest New Drugs 2007;25:453-462.
108. Yeo W, Boyer M, Chung HC, Ong SYK, Lim R, Zee B, Ma B, Lam KC, Mo FKF, Ng EKW, Ho R, Clarke S, Roh JK, Beale P, Rha SY, Jeung HC, Soo R, Goh BC, Chan ATC. Irofulven as first line therapy in recurrent or metastatic gastric cancer: A Phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). Cancer Chemother Pharmacol 2007;59:295-300.
109. Schilder RJ, Blessing JA, Shahin MS, Miller DS, Tewari KS, Muller CY, Warshal DP, McMeekin S, Rotmensch J. A Phase 2 evaluation of Irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer A Gynecologic Oncology Group Trial. Int J Gynecol Cancer 2010;20:1137-1141.
110. Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, Vo ACH, Klucher K, Herbst RS, Eckhardt SG, Peterson S, Hausman DF, Kurzrock R, Jimeno AA. Multicenter Phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2012;18:4173-4182.
111. Clay BF, Bentley MD, Shive W. Structure of triornicin, a new siderophore. Biochemistry 1981;20:2436-2438.
112. Frederick C, Szaniszlo P, Vickrey P, Bentley M, Shive W. Production and isolation of siderophores from the soil fungus Epicoccum purpurascens. Biochemistry 1981;20:2432-2436.
113. Aldridge DC, Burrows BF, Turner WB. Structures of the fungal metabolites cytochalsin E and F. J Chem Soc Chem Comm 1972;3:148-149.
114. Doubravka V, Vesely D, Jelink R. Cytochalasin E: Production by strain Aspergillus clavatus and toxic effects upon embryonic chick. Microbiol Aliment Nutr 1983;4:393-398.
115. El-Kady IA, Mustafa ME. Production of cytochalasin C, D, and E from Dematiaceous hyphomycetes. Folia Microbiol (Prague) 1995;40:301-303.
116. Wagenaaar MM, Corwin J, Strobel G, Clardy J. Thre new cytochalasins produced by an endophytic fungus in the genus Rhinocladiella. J Nat Prod 2000;63:1692-1695.
117. Liu R, Gu Q, Zhu W, Cui C, Fan G, Fang Y, Zhu T, Liu H. 10-Phenyl-[12]-cytochalasins Z7, Z8, and Z9 from the marine derived fungus Spicaria elegans. J Nat Prod 2006;69:871-875.
118. Xiao L, Liu H, Wu N, Liu M, Wei J, Zhang Y, Lin X. Characterization of the high cytochalsin e and rosellichalasin producibng-Aspergillus sp. nov, F1 from marine solar saltern China. World J Microbiol Biotechnol 2013;29:11-17.
119. Scherlach K, Boettger D, Remme N, Hertweck C. The chemistry and biology of cytochalasans. Nat Prod Rep 2010;27:869-886.
120. Hayot C, Debeir O, Van Ham P, Van Damme M, Kiss R, Decaestecke C. Characterization of the activities of actin-affecting drugs on tumor cell migration. Toxicol Appl Pharmacol 2006;211:30-40.
121. Udagawa T, Yuan J, Panigrahy D, Chang YH, Shah J, D'Amato RJ. Cytochalasin E, an epoxide containing Aspergillus-derived fungal metabolite, inhibits angiogenesis and tumor growth. J Pharmacol Exp Ther 2000;294:421-427.
122. Sassa T, Tokashi M, Kitaguchi T. The structures of cotylenines A, B, C, D and E. Agric Biol Chem 1975;39:1735-1744 (and references therein cited).
123. Sassa T. Promotion of the enlargement of cotyledons by cotylenins A and B. Agric Biol Chem 1970;34:1588-1589.
124. Sassa T. Cotylenins, leaf growth substances produced by a fungus. Isolation and characterization of cotylenins A and B. Agric Biol Chem 1971;35:1515-1518.
125. Sassa T, Negoro T, Ueki H. Cotylenin, leaf growth produced by a fungus. II Production of a new fungal metabolites, cotylenol. Agric Biol Chem 1972;36:2281-2285.
126. Honma Y, Ishii Y, Sassa T, Asahi K. Treatment of human promyelocytic leukemia in the SLID mouse model with cotylenin A, an inducer of myelomonocytic differentiation of leukemia cells. Leuk Res 2003;27:1019-1025.
127. Sailer M, Sasek V, Sejbal J, Budesinky M, MUsilek V. Flavovirin-A new antifungal antibiotic produced by the pyrenomycete Melanconis flavovirens. J Basic Microbiol 1989;29:375-381.
128. Fujita T, Inoue K, Yamamoto S, Ikumoto T, Sasaki S, Toyama R, Chiba K, Hoshino Y, Okumoto T. Fungal metaboltes. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot 1994;47:208-215.
129. Sasaki S, Hashimoto R, Kiuchi M, Inoue K, Ikumoto T, Hirose R, Chiba K, Hoshino Y, Okumoto T, Fujita T. Fungal metabolites. Part 14. Novel potent immunosuppresants, mycestericins, produced by Mycelia sterilia. J Antibiot 1994;47:420-433.
130. He Q, Johnson VJ, Osuchowski MF, Sharma RP. Inhibition of serine palmitoyl trnsferase by myoricin, a natural mycotoxin, causes induction of c-myc in mouse liver. Mycopathologia 2004;157:339-347.
131. Krasnoff SB, Reategui RR, Wagenaar MM, Gloer JB, Gibson DM. Cicadapeoptins I and II: New Aib-contining peptides from entomopathogenic fungus Cordyceps heteropoda. J Nat Prod 2005;68:50-55.
132. Sanford M. Fingolimod: A review of its use in relapsing-remitting multiple sclerosis. Drugs 2014;74:1411-1433.
133. Kennedy PC, Zhu R, Huang T, Tomsig JL, Mathews TP, David M, Peyruchaud O, Macdonald TL, Lynch KR. Characterization of a sphingosine 1-phosphate receptor antagonist prodrug. J Pharmacol Exp Ther 2011;338:879-889.
134. Zhang L, Wang H, Zhu J, Ding K, Xu J. FTY720 reduces migration and invasion of human glioblastoma cell lines via inhibiting the PI3K/AKT/mTOR/p70S6K signaling pathway. Tumor Biol 2014;35:10707-10714.
135. Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: Special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 2005;23:2411-2422.
136. Mou Y, Luo H, Mao Z, Shan T, Sun W, Zhou K, Zhou L. Enhancement of palmarumycins C12 and C13 production in liquid culture of endophytic fungus Berkleasmium sp. Dzf12 after treatment with metal ions. Int J Mol Sci 2013;14:979-998.
137. Krohn K, Michel A, Lorke U, Aust H-J, Draeger S, Schulz B. Palmarumycins Cp1-Cp4 from Conyothyrium palmarum. Isolation, structure elucidation, and biological activity. Liebigs Ann Chem 1994;1093-1097.
138. Powis G, Wipf P, Lynch SM, Birmingham A, Kirkpatrick DL. Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors thioredoxin reductase. Mol Cancer Ther 2006;5:630-636.
139. Ritha G, Johansson M, Sterner O. Synthesis of Epi-Galiellalactone Analogs. Abstracts of Papers, in 240th ACS National Meeeting, Boston, MA; 2010 August 22-26.
140. Kopcke B, Weber RWS, Heidrun A. Galiellalactone and its biogenetic precursor as chemotaxonomic markers of the Sarcosomataceae (Ascomycota). Phytochemistry 2002;60:709-714.
141. Johansson M, Kopcke B, Heidrun A, Sterner O. Biologically active secondary metabolites from the ascomycete Aiii-95:2. Structure elucidation. J Antibiot 2002;55:104-106.
142. Johansoon M, Sterner O. Synthesis of (+)-galiellalactone. Absolute configuration of galiellalactone. Org Lett 2001;3:2843-2845.
143. Hellsten R, Johansson M, Sterner O, Bjartell A. Galiellalactone inhibits growth of prostate cancer cell xenografts and induces apoptosis of human prostate cancer cells expressing active Stat3. Eur Urol Suppl 2006;5:797-797.
144. Hellsten R, Johansson M, Dahlman A, Dizeyi N, Sterner O, Bjartell A. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3. Prostate 2008;68:269-280.
145. Don-Doncow N, Escobar Z, Johansson M, Kjellstrom S, Garcia V, Munoz E, Stener O, Bjartell A, Hellsten R. Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells. J Biol Chem 2014;289:15969-15978.
146. Kakeya H, Onose R, Yoshida A, Hiroyuki K, Hiroyuki O. Epoxiquinol B, a fungal metabolite with a potent atiangiogenic activity. J Antibiot 2002;55:829-831.
147. Mitsuru S, Hayashi Y. Chemistry of epoxyquinols A, B, and C and epoxytwinol A. Eur J Org Chem 2007;3783-3800.
148. Ding G, Zhang F, Chen H, Guo L, Zhongmei Z, Yongsheng C. Pestaloquinols A and B, isoprenylated epoxyquinols from Pestalotiopsis sp. J Nat Prod 2011;74:286-291.
149. Kamiyama H, Kakeya H, Usui T, Nishikawa K, Shoji M, Hayashi Y, Osada H. Epoxyquinol B shows antiangiogenic and antitumor effects by inhibiting VEGFR2, EGFR, FGFR, and PDGFR. Oncol Res 2008;17:11-21.
150. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: A meta-analysis. JAMA 2011;305:487-494.
151. Keefe D, Bowen J, Gibson R, Tan T, Okera M, Stringer A. Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: A review. Oncologist 2011;16:432-444.
152. Kapadia S, Hapani S, Choueri TK, Wu S. Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients. Acta Oncol 2013;52:1202-1212.
153. Cartwright TH. Adverse events associated with antiangiogenic agents in combination with cytotoxic chemotherapy in metastatic colorectal cancer and their management. Clin Colorectal Cancer 2013;12:86-94.
154. Funakoshi T, Latif A, Galsky MD. Risk of hematologic toxicities in cancer patients treated with sunitinib: A systematic review and meta-analysis. Cancer Treat Rev 2013;39:818-830.
155. Bair SM, Choueiri TK, Moslehi J. Cardiovascular complications associated with novel angiogenesis inhibitors: Emerging evidence and evolving perspectives. Trends Cardiovasc Med 2013;23:104-113.
156. Chen Y, Guo H, Du Z, Liu X-Z, Che Y, Ye YX. Ecology screen identifies new metabolites from Cordyceps-clonizing fungus as cancer cell proliferationinhibitors and apoptosis inducers. Cell Proliferation 2009;42:838-847.
157. Figueroa M, Graf TN, Ayers S, Adcock AF, Kroll DJ, Yang J, Swanson SM, Munoz-Acuna U, De Blanco C, Esperanza J, Agrawal R, Wani MC, Darveaux BA, Pearce CJ, Oberlies NH. Cytotoxic epipolythiodioxopiperazine alkaloids from filamentous fungi of the Bionectriaceae. J Antibiot 2012;65:559-564.
158. Jin J-M, Lee S, Lee J, Baek S-R, Kim J-C, Yun S-H, Park S-Y, Kang S, Lee Y-W. Functional characterization and manipulation of the apicidin byosynthetic pathway in Fusarium semitectum. Mol Microbiol 2010;76:456-466.
159. Singh SB, Zink DL, Polishooh GD, Dombrowski AW, Darkin-Rattray SJ, Schmaatz DM, Goetz MA. Apicidins: Novel cyclic tetrapeptides as coccidiostats and antimalarial agents from Fusarium pallidoroseum. Tetrahedron Lett 1996;37:8077-8080.
160. Ahn MY, Chung HY, Choi WS, Lee BM, Yoon S, Kim HS. Anti-tumor effect of apicidin on Ishikawa human endometrial cancer cells both in vitro and in vivo by blocking histone deacetylase 3 and 4. Int J Oncol 2010;36:125-131.
161. Ahn MY, Kang DO, Na YJ, Yoon S, Choi WS, Kang KW, Chung HY, Jung JH, Min DS, Kim HS. Histone deacetylase inhibitor, apicidin, inhibits human ovarian cancer cell migration via class II histone deacetylase 4 silencing. Cancer Lett 2012;325:189-199.
162. Hauser D, Weber HP, Sigg HP. Isolation and structure elucidation of cheatocin. Helv Chim Acta 1970;53:1061-1073.
163. Udagawa S, Muroi T, Kurata H, Semita S, Yoshihira K, Natori S, Umeda N. The production of chaetoglobosins, sterigmatocystin, O-methylsterigmatocystin, and chaetocin by Chaetomium subspecies and related fungi. Can J Microbiol 1979;25:170-177.
164. Li G-Y, Li B-G, Yang T, Liu G-Y, Zang G-L. Secondary metabolites from the fungus Chaetomium brasiliense. Helv Chim Acta 2008;91:124-129.
165. Isham CR, Tibodeau JD, Bossou AR, Merchan JR, Bible KC. The anticancer effects of chaetocin are independent of programmed cell death and hypoxia, and are associated with inhibition of endothelial cell proliferation. Br J Cancer 2012;106:314-323.
166. Chiba T, Saito T, Yuki K, Zen Y, Koide S, Kanogawa N, Motoyama T, Ogasawara S, Suzuki E, Ooka Y, Tawada A, Otsuka M, Miyazaki M, Iwama A, Yokosuka O. Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma. Int J Cancer 2015;136:289-298.
167. Reece KM, Richardson ED, Cook KM, Campbell TJ, Pisle ST, Holly AJ, Venzon DJ, Liewehr DJ, Chau CH, Price DK, Figg WD. Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vitro antitumor activity by disrupting the HIF-1alpha/p300 complex in a preclinical model of prostate cancer. Mol Cancer 2014;13:article number 91.
168. Ma Z, Dong J, Muzhen F, Yunhi L, Li Z. Analysis of pathogenic toxin from Alternaria brassicae. (1) Purification and chemical structure identification of destruxin B. Yunwu Xitong 2000;19:360-365.
169. Parada RY, Oka K, Yamagishi D, Kodama M, Otani H. Destruxin B produced by Alternaria brassicae does not induce accessibility of host plants to fungal invasion. Physiol Mol Plant Pathol 2007;71:48-54.
170. Chen J-W, Liu B-L, Tzeng Y-M. Purification and quantification of destruxins A and B from Metarhizium anisopliae. J Chromatogr 1999;833:115-125.
171. Asai T, Yamamoto T, Chung Y-M, Chang F-R, Wu Y-C, Kouwa Y, Yoshiteru O. Aromatic polyketide glucoside from an entomopathogenic fungus, Cordyceps indigotica. Tetrahedron Lett 2012;53:277-280.
172. Lee Y-P, Wang C-W, Liao W-C, Yang C-R, Yeh C-T, Tsai C-H, Yang C-C, Tzeng Y-M. In vitro and in vitro anticancer effects of destruxin B on human colorectal cancer. Anticancer Res 2012;32:2735-2745.
173. Yeh C-T, Rao Y K, Ye M, Wu W-S, Chang T-C, Wang L-S, Wu C-H, Wu ATH, Tzeng Y-M. Preclinical evaluation of destruxin B as a novel Wnt signaling target suppressing proliferation and metastasis of colorectal cancer using non-invasive bioluminescence imaging. Toxicol Appl Pharmacol 2012;261:31-41.
174. Huynh TT, Rao YK, Lee WH, Chen HA, Le TDQ, Tzeng DTW, Wang LS, Wu ATH, Lin YF, Tzeng YM, Yeh CT. Destruxin B inhibits hepatocellular cell growth through modulation of the Wnt/beta-catenin signaling pathway and epithelial-mesenchymal transition. Toxicol in Vitro 2014;28:552-561.
175. Huang-Liu R, Chen SP, Lu TM, Tsai WY, Tsai CH, Yang CC, Tzeng YM. Selective apoptotic cell death effects of oral cancer cells treated with destruxin B. BMC Complement Altern Med 2014;14, article number 207.
176. Chua CW, Lee DTW, Ling MT, Zhou C, Man K, Ho J, Chan FL, Wang XH, Wong YC. FTY720, a fungus metabolite, inhibits in vitro growth of androgen-independent prostate cancer. Int J Cancer 2005;117:1039-1048.
177. Ng KT, Man K, Ho JW, Sun CK, Lee TK, Zhao Y, Lo CM, Poon RT, Fan ST. Marked suppression of tumor growth by FTY720 in a rat liver tumor model: The significance of down-regulation of cell survival Akt pathway. Int J Oncol 2007;30:375-380.
178. Zheng T, Meng X, Wang J, Chen X, Yin D, Liang Y, Song X, Pan S, Jiang H, Liu L. PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice. J Cell Biochem 2010;111:218-228.
179. Mousseau Y, Mollard S, Faucher-Durand K, Richard L, Nizou A, Cook-Moreau J, Baaj Y, Qiu H, Plainard X, Fourcade L, Funalot B, Sturtz FG. Fingolimod potentiates the effects of sunitinib malate in a rat breast cancer model. Breast Cancer Res Treat 2012;134:31-40.
180. Omar HA, Chou CC, Berman-Booty LD, Ma Y, Hung JH, Wang D, Kogure T, Patel T, Terracciano L, Muthusamy N, Byrd JC, Kulp SK, Chen C-S. Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma. Hepatology 2011;53:1943-1958.
181. Fondy TP, Bogyo D. Cytochalasin compositions and therapeutic methods. Patent number WO90013293; 1990.
182. Fondy TP, Bogyo D. Cytochalasin compositions and therapeutic methods. Patent number EP429585; 1991.
183. Sakurai S, Sassa T, Asahi K, Takahashi N. Cell differentiation inducing agent. Patent number JP1992149133; 1992.
184. Toyomasu T, Sassa T, Dairi T, Kato N. Chimeric fusicoccane synthase and gene of the same family. Patent number WO08129699; 2008.
185. Steinman L, Ho PPK. Combination therapy for treatment of inflammatory demyelinating disease. Patent number WO13022882; 2013.
186. Ma Z. Treatment of type 2 diabetes with FTY720. Patent number US08653026; 2014.
187. Lazo JS, Wipf P, Day BW. Synthesis and methods of use of new antimitotic agents. Patent number US20020049221; 2002.
188. Lazo JS, Wipf P, Day BW. Syntheses and methods of use of new antimitotic agents. Patent number US20046673937; 2004.
189. Powis G, Wipf P. Palmarumycin based inhibitors of thioredoxin and methods of using same. Patent number WO070035641; 2007.
190. Powis G, Wipf P. Palmarumycin based inhibitors of thioredoxin and methods of using same. Patent number EP1933820; 2010.
191. Powis G, Wipf P. Palmarumycin based inhibitors of thioredoxin and methods of using same. Patent number US20090131511; 2009.
192. Takehana K, Umemura T, Nakajo H, Itou S, Kobayashi M. Drug for prevention and treatment of disease by using apicidin. Patent number JP41998226652; 1998.
193. Lee HW, Jung YH, Han JW, Lee SY, Lee YW, Lee HY. Apicidin-derivatives, their synthetic methods and anti-tumor compositions containing them. Patent number US20040014647; 2004.
194. Jung YH, Han JW, Lee SY, Lee YW, Lee HY, Lee HW. Apicidin-derivatives, their synthetic methods and anti-tumor compositions containing them. Patent number US6831061; 2004.
195. De Munari S, Grugni M, Menta E, Cassin M, Colella G. Use of diketodithiopiperazine antibiotics for the preparation of antiangiogenic pharmaceutical compositions. Patent number WO06066775; 2006.
196. De Munari S, Grugni M, Menta E, Cassin M, Collela G. Use of diketodithiopiperazine antibiotics for the preparation of antiangiogenic pharmaceutical compositions. Patent number US20080255099; 2008.
197. Bible KC, Isham CR, Xu R, Tibodeau JD. Methods and compositions for treating cancer. Patent number WO08112014; 2008.
198. Dowd PF, Cole RJ. Control of insects by roseotoxin B. Patent number US4956343; 1990.
199. Sumio A, Kamijo M, Miyajima H. Cardiotonic agent and its production. Patent number JP1997315996; 1997.
200. Nagai K. Pharmaceutical composition for prevention and remedy of osteoporosis. Patent number WO02064155; 2002.
201. Nagai K. Pharmaceutical composition for prevention and remedy of osteoporosis. Patent number US20040102365; 2004.